Literature DB >> 3252752

Temocillin efficacy in experimental Klebsiella pneumoniae meningitis after infusion into rabbit plasma to simulate antibiotic concentrations in human serum.

G Woodnutt1, E J Catherall, I Kernutt, L Mizen.   

Abstract

An infusion system was developed to simulate in the plasma of rabbits the concentrations of temocillin in human serum measured after administration of a 2-g intravenous bolus dose. The efficacy of therapy with this infusion against experimental Klebsiella pneumoniae meningitis was compared with that of a conventional bolus dose to the animals. The marked difference between the elimination half-life (t1/2) of temocillin in rabbit plasma and human serum (0.3 and 5 h, respectively) was reflected in concentrations in cerebrospinal fluid (CSF). The mean peak concentration after infusion occurred 3.5 h later than after bolus dosing, and levels were more prolonged (t1/2 in CSF was 6.3 h compared with 0.83 h following the bolus dose). After infusion, the mean viable count in CSF decreased by 4 log10 CFU/ml, whereas the bolus dose was ineffective because of the rapid fall to subinhibitory concentrations. These results suggest that the infusion system used is valuable for experimental studies with antibacterial agents whose elimination kinetics differ markedly between animals and humans.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3252752      PMCID: PMC175955          DOI: 10.1128/AAC.32.11.1705

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  16 in total

Review 1.  Gram-negative bacillary meningitis.

Authors:  R J Mangi; R Quintiliani; V T Andriole
Journal:  Am J Med       Date:  1975-12       Impact factor: 4.965

2.  A novel method to predict the elimination half-lives and the renal excretion mechanisms of cephalosporins.

Authors:  I Komiya; M Nishio; S Murata; F Chiba; T Sakurai; S Shinkai; M Fujita
Journal:  J Pharmacobiodyn       Date:  1984-08

3.  Animal models in antibacterial drug research.

Authors:  H Mattie
Journal:  J Antimicrob Chemother       Date:  1984-08       Impact factor: 5.790

4.  Pharmacokinetic analysis and calculations using a program for the minicalculator TI-59.

Authors:  F Nielsen-Kudsk
Journal:  Int J Biomed Comput       Date:  1981-01

5.  BRL 17421, a novel beta-lactam antibiotic, highly resistant to beta-lactamases, giving high and prolonged serum levels in humans.

Authors:  B Slocombe; M J Basker; P H Bentley; J P Clayton; M Cole; K R Comber; R A Dixon; R A Edmondson; D Jackson; D J Merrikin; R Sutherland
Journal:  Antimicrob Agents Chemother       Date:  1981-07       Impact factor: 5.191

6.  Antibiotic therapy of infections due to Pseudomonas aeruginosa in normal and granulocytopenic mice: comparison of murine and human pharmacokinetics.

Authors:  A U Gerber; H P Brugger; C Feller; T Stritzko; B Stalder
Journal:  J Infect Dis       Date:  1986-01       Impact factor: 5.226

7.  Prediction of aztreonam pharmacokinetics in humans based on data from animals.

Authors:  E A Swabb; D P Bonner
Journal:  J Pharmacokinet Biopharm       Date:  1983-06

8.  Pharmacokinetics and bacteriological effect of ceftazidime in experimental Streptococcus pneumoniae, Haemophilus influenzae, and Escherichia coli meningitis.

Authors:  Y Sakata; A Boccazzi; G H McCracken
Journal:  Antimicrob Agents Chemother       Date:  1983-02       Impact factor: 5.191

9.  Listeria and gram-negative bacillary meningitis in New York City, 1972-1979. Frequent causes of meningitis in adults.

Authors:  C E Cherubin; J S Marr; M F Sierra; S Becker
Journal:  Am J Med       Date:  1981-08       Impact factor: 4.965

10.  Meningitis caused by gram-negative bacilli.

Authors:  S L Berk; W R McCabe
Journal:  Ann Intern Med       Date:  1980-08       Impact factor: 25.391

View more
  8 in total

1.  Animal models in the evaluation of antimicrobial agents.

Authors:  O Zak; T O'Reilly
Journal:  Antimicrob Agents Chemother       Date:  1991-08       Impact factor: 5.191

2.  Development of a new experimental model of penicillin-resistant Streptococcus pneumoniae pneumonia and amoxicillin treatment by reproducing human pharmacokinetics.

Authors:  L Piroth; L Martin; A Coulon; C Lequeu; M Duong; M Buisson; H Portier; P Chavanet
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

3.  Simulation of human serum pharmacokinetics of ticarcillin-clavulanic acid and ceftazidime in rabbits, and efficacy against experimental Klebsiella pneumoniae meningitis.

Authors:  L Mizen; G Woodnutt; I Kernutt; E J Catherall
Journal:  Antimicrob Agents Chemother       Date:  1989-05       Impact factor: 5.191

4.  Simulation of amoxicillin pharmacokinetics in humans for the prevention of streptococcal endocarditis in rats.

Authors:  U Fluckiger; P Moreillon; J Blaser; M Bickle; M P Glauser; P Francioli
Journal:  Antimicrob Agents Chemother       Date:  1994-12       Impact factor: 5.191

5.  Treatment of experimental endocarditis due to Enterococcus faecalis using once-daily dosing regimen of gentamicin plus simulated profiles of ampicillin in human serum.

Authors:  J Gavaldà; P J Cardona; B Almirante; J A Capdevila; M Laguarda; L Pou; E Crespo; C Pigrau; A Pahissa
Journal:  Antimicrob Agents Chemother       Date:  1996-01       Impact factor: 5.191

6.  Simulation of human serum pharmacokinetics of cefazolin, piperacillin, and BRL 42715 in rats and efficacy against experimental intraperitoneal infections.

Authors:  G Woodnutt; V Berry; L Mizen
Journal:  Antimicrob Agents Chemother       Date:  1992-07       Impact factor: 5.191

Review 7.  Generating Robust and Informative Nonclinical In Vitro and In Vivo Bacterial Infection Model Efficacy Data To Support Translation to Humans.

Authors:  Jürgen B Bulitta; William W Hope; Ann E Eakin; Tina Guina; Vincent H Tam; Arnold Louie; George L Drusano; Jennifer L Hoover
Journal:  Antimicrob Agents Chemother       Date:  2019-04-25       Impact factor: 5.191

Review 8.  Temocillin: Applications in Antimicrobial Stewardship as a Potential Carbapenem-Sparing Antibiotic.

Authors:  Tommaso Lupia; Ilaria De Benedetto; Giacomo Stroffolini; Stefano Di Bella; Simone Mornese Pinna; Verena Zerbato; Barbara Rizzello; Roberta Bosio; Nour Shbaklo; Silvia Corcione; Francesco Giuseppe De Rosa
Journal:  Antibiotics (Basel)       Date:  2022-04-07
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.